Zachary J Reitman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11177136/publications.pdf

Version: 2024-02-01

27 papers	3,843 citations	430874 18 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	7665 citing authors

#	Article	IF	Citations
1	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
2	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
3	Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. Journal of the National Cancer Institute, 2010, 102, 932-941.	6.3	448
4	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3270-3275.	7.1	390
5	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget, 2014, 5, 1515-1525.	1.8	237
6	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	21.4	148
7	The genome-wide mutational landscape of pituitary adenomas. Cell Research, 2016, 26, 1255-1259.	12.0	137
8	Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas. Cancer Research, 2013, 73, 496-501.	0.9	108
9	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE, 2011, 6, e16812.	2.5	100
10	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. Journal of Biological Chemistry, 2014, 289, 23318-23328.	3.4	81
11	The genetic landscape of anaplastic astrocytoma. Oncotarget, 2014, 5, 1452-1457.	1.8	69
12	Exomic Sequencing of Four Rare Central Nervous System Tumor Types. Oncotarget, 2013, 4, 572-583.	1.8	69
13	IDH1 and IDH2: Not Your Typical Oncogenes. Cancer Cell, 2010, 17, 215-216.	16.8	65
14	IDH1 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications, 2010, 398, 585-587.	2.1	58
15	New Directions in the Treatment of Glioblastoma. Seminars in Neurology, 2018, 38, 050-061.	1.4	33
16	Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. Blood, 2015, 125, 336-345.	1.4	25
17	Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology, 2012, 8, 887-889.	8.0	22
18	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications, 2022, 13, 604.	12.8	22

#	Article	IF	Citations
19	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.6	18
20	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 694-699.	2.2	18
21	Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathologica, 2013, 126, 789-792.	7.7	15
22	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. European Journal of Medicinal Chemistry, 2016, 119, 218-230.	5.5	13
23	Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. Seminars in Radiation Oncology, 2022, 32, 3-14.	2.2	11
24	A Modified Nucleoside 6-Thio-2â€²-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.0	10
25	Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 771-779.	0.8	7
26	Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma. Pharmacogenomics, 2014, 15, 1639-1641.	1.3	4
27	A Need for More Molecular Profiling in Brain Metastases. Frontiers in Oncology, 2021, 11, 785064.	2.8	1